文献速递泌尿男性生殖肿瘤

睾酮抑制联合恩扎卢胺对比睾酮抑制联合标准抗雄激素治疗转移性激素敏感性前列腺癌(ENZAMET):一项国际、开放标签、随机、3期试验

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2023-01-01

ENZAMET试验在83个中心随机分配1125例转移性激素敏感性前列腺癌患者,接受睾酮抑制联合恩扎卢胺(563例)或标准非甾体抗雄激素(562例)。中位随访68个月,恩扎卢胺组5年总生存率67%,对照组57%,风险比0.70(95%CI 0.58-0.84;p<0.0001),各预后亚组及同期多西他赛使用亚组获益一致。

要点

  • 恩扎卢胺组5年总生存率67%,对照组57%,HR 0.70(95%CI 0.58-0.84;p<0.0001)。
  • 总生存获益在预设预后亚组及计划同期使用多西他赛者中一致。
  • 恩扎卢胺组3-4级疲乏6% vs 对照组1%,高血压10% vs 6%,1-3级记忆障碍13% vs 4%。

核心结论

  • 在标准治疗基础上加用恩扎卢胺可持续改善转移性激素敏感性前列腺癌患者的总生存,作者认为应将其视为符合条件患者的治疗选择。

研究设计与样本

  • ENZAMET为国际、开放标签、随机、3期试验,在澳大利亚、加拿大、爱尔兰、新西兰、英国和美国的83个中心(包括诊所、医院和大学中心)开展。
  • 纳入18岁及以上男性转移性激素敏感性前列腺腺癌患者,CT或99mTc骨扫描证实转移,ECOG体能状态评分0-2。
  • 2014年3月31日至2017年3月24日共随机分配1125例参与者,1:1接受标准非甾体抗雄激素(562例,对照组)或恩扎卢胺(563例),中位年龄69岁(IQR 63-74)。
  • 恩扎卢胺160 mg每日一次口服;对照组为较弱的标准口服非甾体抗雄激素(比卡鲁胺、尼鲁米特或氟他胺),治疗至临床疾病进展或不可耐受毒性。
  • 允许随机前最多12周开始睾酮抑制并作为辅助治疗最多24个月;允许同期多西他赛75 mg/m2静脉给药,每3周一次,最多6个周期,由参与者和医生决定。

主要发现

  • 恩扎卢胺组中位总生存未达到(HR 0.70 [95%CI 0.58-0.84];p<0.0001),对照组5年总生存率57%(95%CI 0.53-0.61),恩扎卢胺组67%(95%CI 0.63-0.70)。
  • 恩扎卢胺的总生存获益在预设预后亚组(同时性和异时性高瘤量或低瘤量疾病)及计划同期使用多西他赛者中一致。
  • 最常见的3-4级不良事件为多西他赛相关的发热性中性粒细胞减少(对照组558例中33例[6%] vs 恩扎卢胺组563例中37例[6%])、疲乏(4例[1%] vs 33例[6%])和高血压(31例[6%] vs 59例[10%])。
  • 1-3级记忆障碍发生率对照组25例(4%) vs 恩扎卢胺组75例(13%)。
  • 无死亡归因于研究治疗。

临床怎么用

  • 作者认为,在标准治疗基础上加用恩扎卢胺应被视为符合条件患者的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report the planned primary overall survival analysis, with the aim of defining the benefit of enzalutamide treatment in different prognostic subgroups (synchronous and metachronous high-volume or low-volume disease) and in those who received concurrent docetaxel. METHODS: ENZAMET is an international, open-label, randomised, phase 3 trial conducted at 83 sites (including clinics, hospitals, and university centres) in Australia, Canada, Ireland, New Zealand, the UK, and the USA. Eligible participants were males aged 18 years or older with metastatic, hormone-sensitive prostate adenocarcinoma evident on CT or bone scanning with 99mTc and an Eastern Cooperative Oncology Group performance status score of 0-2. Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 mg once per day) or a weaker standard oral non-steroidal antiandrogen (bicalutamide, nilutamide, or flutamide; control group) until clinical disease progression or prohibitive toxicity. Testosterone suppression was allowed up to 12 weeks before randomisation and for up to 24 months as adjuvant therapy. Concurrent docetaxel (75 mg/m2 intravenously) was allowed for up to six cycles once every 3 weeks, at the discretion of participants and physicians. The primary endpoint was overall survival in the intention-to-treat population. This planned analysis was triggered by reaching 470 deaths. This study is registered with ClinicalTrials.gov, NCT02446405, ANZCTR, ACTRN12614000110684, and EudraCT, 2014-003190-42. FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63-74). This analysis was triggered on Jan 19, 2022, and an updated survival status identified a total of 476 (42%) deaths. After a median follow-up of 68 months (IQR 67-69), the median overall survival was not reached (hazard ratio 0·70 [95% CI 0·58-0·84]; p<0·0001), with 5-year overall survival of 57% (0·53-0·61) in the control group and 67% (0·63-0·70) in the enzalutamide group. Overall survival benefits with enzalutamide were consistent across predefined prognostic subgroups and planned use of concurrent docetaxel. The most common grade 3-4 adverse events were febrile neutropenia associated with docetaxel use (33 [6%] of 558 in the control group vs 37 [6%] of 563 in the enzalutamide group), fatigue (four [1%] vs 33 [6%]), and hypertension (31 [6%] vs 59 [10%]). The incidence of grade 1-3 memory impairment was 25 (4%) versus 75 (13%). No deaths were attributed to study treatment. INTERPRETATION: The addition of enzalutamide to standard of care showed sustained improvement in overall survival for patients with metastatic hormone-sensitive prostate cancer and should be considered as a treatment option for eligible patients. FUNDING: Astellas Pharma.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023. PMID: 36990608. doi:10.1016/S1470-2045(23)00063-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。